The Diagnosis and Treatment of Resistant Hypertension, the Prevalence and the Prognosis (doublepres)
The Prevalence and the Prognosis of Resistant Hypertension Ascertained With Systemic Investigation and Optimal Treatment With Antihypertensive Drugs
Sponsor: Chinese Academy of Medical Sciences, Fuwai Hospital
Listed as NCT01703780, this observational or N/A phase trial focuses on Hypertension, Resistant to Conventional Therapy and remains ongoing. Sponsored by Chinese Academy of Medical Sciences, Fuwai Hospital, it has been updated 12 times since 2012, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Unknown
-
Sep 2024 — Sep 2025 [monthly]
Unknown
-
Jul 2024 — Sep 2024 [monthly]
Unknown
Status: Unknown Status → Unknown
-
Dec 2021 — Jul 2024 [monthly]
Unknown Status
-
Jan 2021 — Dec 2021 [monthly]
Unknown Status
▶ Show 7 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Unknown Status
-
Jan 2019 — Nov 2020 [monthly]
Unknown Status
Status: Active Not Recruiting → Unknown Status
-
Jun 2018 — Jan 2019 [monthly]
Active Not Recruiting
-
May 2018 — Jun 2018 [monthly]
Active Not Recruiting
-
Apr 2018 — May 2018 [monthly]
Active Not Recruiting
Phase: NA → None
-
Aug 2017 — Apr 2018 [monthly]
Active Not Recruiting NA
-
Jan 2017 — Aug 2017 [monthly]
Active Not Recruiting NA
First recorded
Jul 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Chinese Academy of Medical Sciences, Fuwai Hospital
- Huazhong University of Science and Technology
- Shanghai Jiao Tong University School of Medicine
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Beijing, China , Changchun, China , Chengdu, China , Fuzhou, China , Guangzhou, China , Jining, China , Qingdao, China , Rizhao, China , Shanghai, China , Shuangyashan, China and 6 more locations